NEW YORK (GenomeWeb) — Australian Clinical Labs said on Tuesday that it has signed an agreement to take over the clinical pathology and reporting services of Genome.One, a subsidiary of the Garvan Institute of Medical Research.
Genome.One was established in 2016 to offer clinical whole-genome sequencing for the diagnosis of rare genetic conditions. Sydney-based Genome.One has since expanded its offerings to include discovery genomics services, precision medicine software, and consumer-focused genomics testing.
Under the terms of the deal, Clinical Labs will assume responsibility for Genome.One's clinical pathology and reporting activities, working with researchers at Garvan, where all whole-genome sequencing will be performed.
"Genome.One's genome pathology service team will become part of Clinical Labs and remain located in Sydney at the Garvan Institute," Clinical Labs CEO Melinda McGrath said in a statement. "Our molecular genetics team will work closely with the Garvan researchers and their sequencing team to build a bigger and more advanced precision medicine pathology service."
Additional terms of the agreement were not disclosed.